Vitamin D, calcidiol and calcitriol regulate vitamin D metabolizing enzymes in cervical and ovarian cancer cells

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4429-4434

  Kloss, Martin ^a   Fischer, Dorothea ^a   Thill, Marc ^a   Friedrich, Michael ^b   Cordes, Tim ^a   Salehin, Darius ^b   Diedrich, Klaus ^a   Köster, Frank ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b HELIOS Clinic Krefeld   (Germany)

Author keywords

1 hydroxylase; 24 hydroxylase; 25 hydroxylase; Calcidiol; Calcitriol; Cervical cancer; Ovarian cancer; Vitamin D

Indexed keywords

25 HYDROXYLASE; 25 HYDROXYVITAMIN D; CALCITRIOL; MESSENGER RNA; OXYGENASE; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADENOCARCINOMA; CALCIFEDIOL; CALCITRIOL; FEMALE; HUMANS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VITAMIN D; VITAMINS;

EID: 78650236614     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr
2. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB and Holick MF: The role of vitamin D in cancer prevention. Am J Public Health 96: 252-261, 2006.
3. Grant WB and Garland CF: The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res 26: 2687-2699, 2006.
4. Cheng JB, Motola DL, Mangelsdorf DJ and Russell DW: De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 278: 38084-38093, 2003.
5. Brown AJ: Regulation of vitamin D action. Nephrol Dial Transplant 14: 11-16, 1999.
6. Ohyama Y and Yamasaki T: Eight cytochrome P450s catalyze vitamin D metabolism. Front Biosci 9: 3007-3018, 2004.
7. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W and Reichrath J: Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164: 239-246, 2003.
8. Norman AW: From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88: 491S-499S, 2008.
9. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K and Narvaez CJ: Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 133: 2425S-2433S, 2003.
10. Bareis P, Kallay E, Bischof MG, Bises G, Hofer H, Potzi C, Manhardt T, Bland R and Cross HS: Clonal differences in expression of 25-hydroxyvitamin D(3)-lalpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Exp Cell Res 276: 320-327, 2002.
11. Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H and Armbrecht HJ: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 134: 1207S-1212S, 2004.
12. Van den Bemd GJ and Chang GT: Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3: 85-94, 2002.
13. Mehta RG and Mehta RR: Vitamin D and cancer. J Nutr Biochem 13: 252-264, 2002.
14. Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF and Koumenis C: Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25: 1015-1026, 2004.
15. Barreto AM, Schwartz GG, Woodruff R and Cramer SD: 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9: 265-270, 2000.
16. Hsu JY, Feldman D, McNeal JE and Peehl DM: Reduced 1 alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61: 2852-2856, 2001.
17. Miller GJ, Stapleton GE, Hedlund TE and Moffat KA: Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1: 997-1003, 1995.
18. Skowronski RJ, Peehl DM and Feldman D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993.
19. Alagbala AA, Moser MT, Johnson CS, Trump DL and Foster BA: Characterization of Vitamin D insensitive prostate cancer cells. J Steroid Biochem Mol Biol 103: 712-716, 2007.
20. Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57: 234-240, 2006.
21. Diesing D, Cordes T, Fischer D, Diedrich K and Friedrich M: Vitamin D-metabolism in the human breast cancer cell line MCF-7. Anticancer Res 26: 2755-2759, 2006.
22. Kemmis CM, Salvador SM, Smith KM and Welsh J: Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136: 887-892, 2006.
23. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD and Feldman D: Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92: 131-141, 2004.
24. Christopherson WA, Porter JC, MacDonald PC and Casey ML: Responsiveness of human carcinoma cells of gynecologic origin to 1,25-dihydroxycholecalciferol. Am J Obstet Gynecol 155: 1293-1296, 1986.
25. Fischer D, Thome M, Becker S, Cordes T, Diedrich K, Friedrich M and Thill M: Expression of 25-hydroxyvitamin D3-24-hydroxylase in benign and malignant ovarian cell lines and tissue. Anticancer Res 29: 3635-3639, 2009.
26. Lou YR, Qiao S, Talonpoika R, Syvala H and Tuohimaa P: The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 92: 317-325, 2004.
27. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11: 3579-3586, 2005.
28. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25: 144-146, 2000.
29. Ly LH, Zhao XY, Holloway L and Feldman D: Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140: 2071-2076, 1999.
30. Ahonen MH, Zhuang YH, Aine R, Ylikomi T and Tuohimaa P: Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 86: 40-46, 2000.
31. Jiang F, Li P, Fornace AJ Jr, Nicosia SV and Bai W: G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 278: 48030-48040, 2003.
32. Li P, Li C, Zhao X, Zhang X, Nicosia SV and Bai W: p27(Kip1) stabilization and G(1) arrest by 125-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 279: 25260-25267, 2004.
33. Fischer D, Becker S, Cordes T, Bucker B, Diedrich K, Friedrich M, Salehin D and Thill M: Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res 29: 3641-3645, 2009.
34. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS and Trump DL: CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 103: 334-337, 2007.